Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2019-04-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
2018年年度股东大会的法律意见
Regulatory Filings Classification · 95% confidence The document text is extremely short (387 characters) and contains only references to omitted pictures with no substantive text content or financial data. There is no indication of any report content, financial statements, or detailed information. Given the lack of content and the presence of placeholders for images, this document does not represent a full report or detailed filing. It is likely a placeholder or an announcement-type document without substantive data. According to the rules, such minimal content with no financial or report data should be classified as Regulatory Filings (RNS) as a fallback category.
2019-04-29 Chinese
2019年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2019 年第一季度报告" which translates to "2019 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary for the first quarter of 2019. The report includes actual financial figures, comparisons to prior periods, and explanations of significant changes. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. The content and structure align with an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year. There is no indication that this is an announcement of a report or a certification document. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2019
2019-04-29 Chinese
关于部分限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from 普莱柯生物工程股份有限公司 regarding the completion of a repurchase and cancellation of restricted shares. It details the board approval, the number of shares repurchased and cancelled, the impact on total share capital, and procedural steps taken. The content focuses on share repurchase and capital reduction, with no financial statements or earnings data. The document length is short (1197 characters) and it is a formal announcement of a share capital change due to repurchase and cancellation of restricted stock. This fits the category of Transaction in Own Shares (POS), which covers company buybacks or share cancellations.
2019-04-26 Chinese
2018年度股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the 2018 Annual General Meeting (AGM) of 普莱柯生物工程股份有限公司, dated April 2019. It contains detailed meeting instructions, agenda, and multiple proposals for shareholder approval, including the 2018 annual report, board and supervisory board work reports, independent directors' reports, financial statements summary, profit distribution plan, auditor appointment, and other corporate governance matters. The content is typical of AGM materials, providing shareholders with information to vote on key company reports and decisions. It is not the annual report itself but the meeting materials for the AGM where the annual report and other reports are presented and approved. The document length is substantial (15,000 characters), consistent with detailed AGM materials. Therefore, the filing type is AGM Information (AGM-R).
2019-04-12 Chinese
审计报告
Regulatory Filings
2019-03-29 Chinese
2018年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2018 年度内部控制评价报告' which translates to '2018 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2018. The content includes detailed descriptions of internal control scope, standards, defect classifications, and conclusions about the effectiveness of internal controls, both financial and non-financial. It is a comprehensive report on internal control evaluation rather than a brief announcement or certification. The document length is 4619 characters, which is sufficient to contain substantive content. This type of report is typically classified as an Audit Report / Information (AR) because it focuses on internal control evaluation and audit opinions related to financial reporting controls, rather than being a full annual report or other filing types. Therefore, the appropriate classification is AR with high confidence. FY 2018
2019-03-29 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.